On methods to utilize HIV-RNA data measured by two different PCR assays

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 4, 2008, Pages 724-736

  Joshua Chen, Y H ^a   Fan, Chunpeng ^b   Zhao, Jing ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI   (France)

Author keywords

HIV RNA; Limit of quantification

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; RESEARCH DESIGN; RNA, VIRAL;

EID: 46749097955     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400802073168     Document Type: Article

References (17)

1. Albert, J. M., Ioannidis, J. P. A., Reichelderfer, P., et al. (1998). Statistical issues for HIV surrogate endpoints: point/counterpoint. Statistics in Medicine 17:2435-2462.
2. Amplicor HIV-1 Monitor™ Test (Standard/UltraSensitive) (1999). Roche Diagnostic Systems, Inc. U.S. Food and Drug administration (FDA) Label.
3. Hallahan, C. (1989). The Tobit Model: An Example of Maximum Likelihood Estimation with SAS/IML. SAS Institute Inc. SAS/STAT user's guide, Version 6. 4th ed. Vol 2. Cary, NC: SAS Institute.
4. Hughes, M. D., Johnson, V. A., Hirsch, M. S., et al. (1997). Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med. 126:929-938.
5. Hughes, M. D. (2000). Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Statistics in Medicine 19:3171-3191.
6. Henry, S. L. (2001). Maximum likelihood inference for left-censored HIV-RNA data. Statistics in Medicine 20:33-45.
7. Johnson, N. L., Kotz, S. (1970). Continuous Univariate Distributions-I: Distributions in Statistics. New York: Wiley.
8. Katlama, C., Berger, D., Bellos, N., et al. (2005). Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. 12th Conference on Retroviruses and Opportunistic Infections, Boston.
9. Lyles, R. H., Williams, J. K., Chuachoowong, R. (2001). Correlating two viral load assays with known detection limits. Biometrics 57:1238-1244.
10. Lazzarin, A., Clotet, B., Cooper, D., et al., for the TORO 2 Study Group. (2003). Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348:2186-2195.
11. Lalezari, J. P, Henry, K., O'Hearn, M., et al. (2003). For the TORO 1 Study Group. Efficacy of Enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348:2175-2185.
12. Mellors, J. W., Rinaldo, C. R., Gupta P., et al. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
13. Murray, J. S., Elashoff, M. R., Iacono-Connors, L. C., Cvetkovich, T. A., Struble, K. A. (1999). The use of plasma HIV-RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 13:797-804.
14. Marschner, I. C., Betensky, R. A., De Gruttola, V., Hammer, S. M., Kuritzkes, D. R. (1999). Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 20:220-227.
15. Sun, R., Ku, J., Jayakar, H., Kuo, J. C., Brambilla, D., Herman, S., Rosenstraus, M., Spadoro, J. (1998). Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 36:2964-2969.
16. Suleiman, J., Rhodes, R., Campo, R., Piliero, P., Steigbigel, R., Chen, J., Winchell, G., Saah, A. (2001). Preliminary results from indinavir (IDV) and ritonavir (RTV) in a once-daily regimen (Merck 103/104). 8th Conference on Retroviruses and Opportunistic Infections, Chicago.
17. Tobin, J. (1958). Estimation of relationships for limited dependent variables. Econometrica 26:24-36.